Mary Chapman, features writer —

Mary graduated from Wayne State University with a degree in journalism. She began her career at United Press International, then spent a decade reporting for the Bureau of National Affairs, Inc. (now Bloomberg Industry Group). Mary has written extensively for The New York Times, and her work has appeared in publications such as Time, Newsweek, Fortune, and the Chicago Tribune. She’s won a Society of Professional Journalists award for outstanding reporting.

Articles by Mary Chapman

Supporters Gear Up for aHUS Awareness Day on Sept 24

From participating in an organ donor registration drive to sharing a community video project, supporters globally are poised to mark the 7th annual aHUS Awareness Day on Sept. 24. The event seeks to heighten visibility around atypical hemolytic uremic syndrome (aHUS), highlight the latest research, and underscore the needs…

EveryLife Introduces First of Kind ‘Roadmap’ to ICD Codes

To help patient advocacy leaders and their partners better understand how global health statistics codes — known as ICD codes — are assigned, updated, and revised in the U.S. health information system, the EveryLife Foundation for Rare Diseases is presenting a first-of-its-kind resource guide. The foundation created the…

Shoshin for aHUS Patients

If you are living with a chronic disease such as atypical hemolytic uremic syndrome (aHUS), a concept called shoshin may help to change your perspective, allowing you see the world, and your disorder, in a different light. What is shoshin? The word shoshin comes from Zen Buddhism, and means “beginner’s…

Rare Disease Day at NIH, Set for March 1, Growing Year by Year

Rare Disease Day at NIH, organized by the National Institutes of Health (NIH) and taking place on March 1, will feature panel discussions, patient stories, research updates, TED-style talks, and a presentation by a Nobel laureate recently recognized for her work on a gene editing tool. The free, virtual…

About OneSource for aHUS Patients

If you have atypical hemolytic uremic syndrome (aHUS) and are being treated with Soliris (eculizumab) or Ultomiris (ravulizumab-cwvz), you may wish to consider enrolling in OneSource, a complimentary and personalized patient support program by Alexion, the therapies’ manufacturer. What is aHUS? aHUS is a rare multi-organ disorder…